{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:49:13Z","timestamp":1789224553802,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-026-03216-8","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:44:54Z","timestamp":1780555494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Abat","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha Imran","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftikhar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushbakhat","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6830-4529","authenticated-orcid":false,"given":"Ehsanullah","family":"Alokozay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soban Ali","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammara","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaiq","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Siddique","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Javed","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Sandoval-Sus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"1","key":"3216_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006.","journal-title":"Pathology"},{"issue":"1","key":"3216_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.leu.2404449","volume":"21","author":"P De Paepe","year":"2007","unstructured":"De Paepe P, De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia. 2007;21(1):37\u201343. https:\/\/doi.org\/10.1038\/sj.leu.2404449.","journal-title":"Leukemia"},{"issue":"2","key":"3216_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146\u201371. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.12.009.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"3216_CR4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ajh.25460","volume":"94","author":"Y Liu","year":"2019","unstructured":"Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604\u201316. https:\/\/doi.org\/10.1002\/ajh.25460.","journal-title":"Am J Hematol"},{"issue":"9","key":"3216_CR5","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s12094-023-03206-5","volume":"25","author":"J Gum\u00e0","year":"2023","unstructured":"Gum\u00e0 J, Palaz\u00f3n-Carri\u00f3n N, Rueda-Dom\u00ednguez A, Sequero S, Calvo V, Garc\u00eda-Arroyo R, et al. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022). Clin Transl Oncol. 2023;25(9):2749\u201358. https:\/\/doi.org\/10.1007\/s12094-023-03206-5.","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"3216_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066\u201373.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3216_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4143\/crt.2022.008","volume":"55","author":"JH Yi","year":"2023","unstructured":"Yi JH, Jeong SH, Kim SJ, Yoon DH, Kang HJ, Koh Y, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from two prospective Korean cohorts. Cancer Res Treat. 2023;55(1):325\u201333. https:\/\/doi.org\/10.4143\/crt.2022.008.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"3216_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10238-024-01306-2","volume":"24","author":"H Chen","year":"2024","unstructured":"Chen H, Zhao J, Zhao D, Wang W, Wei C, Wang Z, et al. Lymphoma relapse 1 year or later after immunochemotherapy in DLBCL patients: clinical features and outcome. Clin Exp Med. 2024;24(1):48. https:\/\/doi.org\/10.1007\/s10238-024-01306-2.","journal-title":"Clin Exp Med"},{"issue":"5","key":"3216_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1053\/j.seminhematol.2023.12.001","volume":"60","author":"N Fabbri","year":"2023","unstructured":"Fabbri N, Mussetti A, Sureda A. Second-line treatment of diffuse large B-cell lymphoma: evolution of options. Semin Hematol. 2023;60(5):305\u201312. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.12.001.","journal-title":"Semin Hematol"},{"issue":"4","key":"3216_CR10","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3324\/haematol.2023.283459","volume":"109","author":"PF Caimi","year":"2024","unstructured":"Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024;109(4):1184\u201393. https:\/\/doi.org\/10.3324\/haematol.2023.283459.","journal-title":"Haematologica"},{"issue":"10","key":"3216_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","volume":"131","author":"F Zammarchi","year":"2018","unstructured":"Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131(10):1094\u2013105. https:\/\/doi.org\/10.1182\/blood-2017-10-813493.","journal-title":"Blood"},{"key":"3216_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221087511","volume":"13","author":"F Furqan","year":"2022","unstructured":"Furqan F, Hamadani M. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. Ther Adv Hematol. 2022;13:20406207221087511. https:\/\/doi.org\/10.1177\/20406207221087511.","journal-title":"Ther Adv Hematol"},{"key":"3216_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"9","key":"3216_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"issue":"3","key":"3216_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3324\/haematol.2024.284973","volume":"110","author":"N Lin","year":"2025","unstructured":"Lin N, Sun X, Zhou H, Zou L, Zhou K, Liu L, et al. Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial. Haematologica. 2025;110(3):683\u201392. https:\/\/doi.org\/10.3324\/haematol.2024.284973.","journal-title":"Haematologica"},{"issue":"19","key":"3216_CR16","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","volume":"137","author":"M Hamadani","year":"2021","unstructured":"Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O\u2019Connor OA, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634\u201345. https:\/\/doi.org\/10.1182\/blood.2020007512.","journal-title":"Blood"},{"issue":"1","key":"3216_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01195-4","volume":"14","author":"N Epperla","year":"2024","unstructured":"Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, et al. Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood Cancer J. 2024;14(1):210. https:\/\/doi.org\/10.1038\/s41408-024-01195-4.","journal-title":"Blood Cancer J"},{"issue":"S1","key":"3216_CR18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174257","volume":"142","author":"E Ayyers","year":"2023","unstructured":"Ayyers E, Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, et al. Loncastuximab in high-risk and heavily pretreated relapsed\/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Blood. 2023;142(S1):312. https:\/\/doi.org\/10.1182\/blood-2023-174257.","journal-title":"Blood"},{"issue":"4","key":"3216_CR19","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/j.clml.2024.11.014","volume":"25","author":"LJ Nastoupil","year":"2025","unstructured":"Nastoupil LJ, Andersen CR, Ayers A, Wang Y, Habermann TM, Chihara D, et al. Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed\/Refractory Aggressive Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2025;25(4):e183-e199.e8. https:\/\/doi.org\/10.1016\/j.clml.2024.11.014.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"3216_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41409-023-02148-4","volume":"59","author":"M Iqbal","year":"2024","unstructured":"Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, et al. Efficacy of CD19 directed therapies in patients with relapsed or refractory large B-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplant. 2024;59(2):211\u20136. https:\/\/doi.org\/10.1038\/s41409-023-02148-4.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3216_CR21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A. Loncastuximab Tesirine: first approval. Drugs. 2021;81(10):1229\u201333. https:\/\/doi.org\/10.1007\/s40265-021-01550-w.","journal-title":"Drugs"},{"issue":"2","key":"3216_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155\u201365. https:\/\/doi.org\/10.1200\/JCO.19.00172.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3216_CR23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, Tournilhac O, Jurczak W, Liberati AM, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978\u201388. https:\/\/doi.org\/10.1016\/S1470-2045(20)30225-4.","journal-title":"Lancet Oncol"},{"key":"3216_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03169-9","author":"K Wilson","year":"2025","unstructured":"Wilson K, Chiodi F, Paine A, Hakimi Z, Ward V, Macmillan T, et al. Loncastuximab Tesirine versus Polatuzumab Vedotin plus Bendamustine and Rituximab in relapsed\/refractory DLBCL after \u22652 lines of therapy: matching-adjusted indirect comparison. Adv Ther. 2025. https:\/\/doi.org\/10.1007\/s12325-025-03169-9.","journal-title":"Adv Ther"},{"key":"3216_CR25","unstructured":"Tesoro D, Fong R, Deni J, Alderuccio JP, Kahl B, Ai W, et al. A pooled safety analysis of loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma in the LOTIS clinical trial program: incidence, onset, and management of myelosuppression [poster]. Available from: https:\/\/www.adctmedical.com\/wp-content\/uploads\/2023\/06\/HOPA-2022_Tesoro_402-101-and-201_Myelosuppression_Poster_FINAL.pdf."},{"issue":"14","key":"3216_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147580","volume":"25","author":"LM Ju\u00e1rez-Salcedo","year":"2024","unstructured":"Ju\u00e1rez-Salcedo LM, Nimkar S, Coraz\u00f3n AM, Dalia S. Loncastuximab Tesirine in the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma. Int J Mol Sci. 2024;25(14):7580. https:\/\/doi.org\/10.3390\/ijms25147580.","journal-title":"Int J Mol Sci"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-026-03216-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03216-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03216-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T02:21:30Z","timestamp":1786328490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-026-03216-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3216"],"URL":"https:\/\/doi.org\/10.1186\/s13643-026-03216-8","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is a systematic review and meta-analysis based entirely on previously published data. No new human participants or animals were involved; therefore, ethical approval and informed consent were not required. The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"217"}}